Table 3

Secondary Outcomes by Main Effects Group

OutcomeOMT vs Sham OMT UST vs Sham UST
OMT (n = 230)Sham OMT (n = 225)P ValueUST (n = 233)Sham UST (n = 222)P Value
RMDQ score, median (IQR)a
  Week 44 (2-8)5 (2-9).324 (2-9)5 (2-8).99
  Week 83 (1-7)3 (2-8).143 (1-8)4 (1-7).76
  Week 122 (1-6)3 (1-7).073 (1-7)3 (1-7).93
SF-36 GH score, median (IQR)b
  Week 471 (55-82)72 (52-86).3972 (54-87)72 (52-82).73
  Week 872 (57-85)72 (52-85).6172 (54-85)72 (57-85).53
  Week 1272 (52-87)72 (57-87).8772 (52-87)74 (54-87).66
Lost 1 or more work days in past 4 weeks because of LBP, % (95% CI)c
  Week 410 (4-16)14 (7-21).4116 (9-23)7 (2-12).04
  Week 86 (2-11)19 (12-27).00517 (10-24)8 (3-14).054
  Week 1211 (5-17)8 (3-13).4113 (6-19)6 (1-11).11
Very satisfied with back care, % (95% CI)d
  Week 452 (46-59)34 (28-41)<.00141 (35-48)45 (38-52).44
  Week 861 (54-67)39 (33-46)<.00149 (43-56)51 (44-58).77
  Week 1266 (60-73)43 (36-50)<.00155 (48-61)55 (48-62).99
LBP co-treatment during study, % (95% CI)e
  Exercise programs19 (14-24)20 (14-25).8220 (15-25)18 (13-24).73
  Lumbar supports1 (0-3)1 (0-2)>.991 (0-2)1 (0-3).68
  Nonprescription drugs46 (39-52)45 (39-52).9546 (40-53)45 (38-51).71
  Prescription drugs13 (9-18)20 (15-26).04816 (11-21)18 (13-23).54
  CAM therapies15 (11-20)17 (12-22).6316 (12-21)16 (11-21).87
  Physical therapy11 (7-15)8 (4-11).179 (5-13)10 (6-14).74
  Hospitalization0 (0-0)0 (0-1).490 (0-1)0 (0-0)>.99
  Surgery0 (0-1)0 (0-0)>.990 (0-0)0 (0-1).49
  • CAM = complementary and alternative medicine; IQR = interquartile range; LBP = low back pain; OMT = osteopathic manual treatment; RMDQ = Roland-Morris Disability Questionnaire; SF-36 GH = Medical Outcomes Study Short Form-36 Health Survey general health scale; UST = ultrasound therapy.

  • a Higher scores on the RMDQ represent greater disability. P values at each endpoint based on the Mann-Whitney test; N = 455 for all endpoints.

  • b Higher scores on the SF-36 GH represent better health. P values at each endpoint based on the Mann-Whitney test; N = 455 for all endpoints.

  • c Work disability analyses limited to the 215 patients employed full-time at baseline; n = 207, 211, and 211 at the successive endpoints.

  • d n = 416, 426, and 429 at the successive endpoints.

  • e N = 455 for all chronic LBP co-treatments.